Cartesian Therapeutics(DE:1S70)
€6.00+0.15 (+2.56%)
DE:1S70
Cartesian Therapeutics stock drug pipeline
€6.00
At close:+0.15 (+2.56%)
Cartesian Therapeutics (1S70) Drug Pipeline
1 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cartesian Therapeutics, Inc. (DE:1S70) have in its pipeline
Cartesian Therapeutics DE:1S70 is currently developing the following drugs: Descartes-08, Decartes-08, Descartes-15, Descartes-25, Descartes 11, Cyclophosphamide, Fludarabine, Descartes-11. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

